SB
Samsara BioCapital Portfolio holdings
AUM
$489M
This Quarter Return
-10.09%
1 Year Return
+135.25%
3 Year Return
+909.96%
5 Year Return
+774.56%
10 Year Return
–
AUM
$327M
AUM Growth
+$327M
(-43%)
Cap. Flow
-$166M
Cap. Flow
% of AUM
-50.7%
Top 10 Holdings %
Top 10 Hldgs %
69.58%
Holding
50
New
3
Increased
3
Reduced
–
Closed
9
Top Buys
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$41M |
| 2 |
INZY
Inozyme Pharma
INZY
|
$6.56M |
| 3 |
Gossamer Bio
GOSS
|
$5.11M |
| 4 |
IO Biotech
IOBT
|
$3.71M |
| 5 |
HilleVax
HLVX
|
$2.69M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Mineralys Therapeutics
MLYS
$1.03B
| $43M | 13.16% | 4,519,361 | – | – |
|
|
RYZB
2
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $41M | 12.54% | +1,845,948 | New | +$41M |
|
3
Scholar Rock
SRRK
$3.14B
| $32.7M | 9.99% | 4,598,828 | – | – |
|
|
SLRN
4
DELISTED
ACELYRIN
SLRN
| $24.2M | 7.41% | 2,381,579 +125,557 | +6% | +$1.28M |
|
5
Arcellx
ACLX
$3.85B
| $22M | 6.74% | 613,921 | – | – |
|
|
LENZ
6
LENZ Therapeutics
LENZ
$1.1B
| $21M | 6.42% | 8,459,314 | – | – |
|
|
ICPT
7
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $11.9M | 3.64% | 640,688 | – | – |
|
8
Lyra Therapeutics
LYRA
$11.5M
| $10.9M | 3.33% | 2,780,261 | – | – |
|
|
9
HilleVax
HLVX
$105M
| $10.8M | 3.29% | 799,274 +200,000 | +33% | +$2.69M |
|
|
AVDL
10
Avadel Pharmaceuticals
AVDL
$1.43B
| $9.97M | 3.05% | 967,527 | – | – |
|
11
Zymeworks
ZYME
$1.12B
| $9.25M | 2.83% | 1,458,875 | – | – |
|
12
Rhythm Pharmaceuticals
RYTM
$6.85B
| $7.92M | 2.42% | 345,293 | – | – |
|
13
Tango Therapeutics
TNGX
$747M
| $7.09M | 2.17% | 630,000 | – | – |
|
|
INZY
14
DELISTED
Inozyme Pharma
INZY
| $6.56M | 2.01% | +1,562,500 | New | +$6.56M |
|
15
Sutro Biopharma
STRO
$72.7M
| $5.81M | 1.78% | 1,675,579 | – | – |
|
|
VRNA
16
Verona Pharma
VRNA
$9.16B
| $5.66M | 1.73% | 347,500 | – | – |
|
|
17
IO Biotech
IOBT
$104M
| $5.13M | 1.57% | 3,640,015 +2,631,578 | +261% | +$3.71M |
|
|
18
Gossamer Bio
GOSS
$562M
| $5.11M | 1.56% | +6,130,268 | New | +$5.11M |
|
19
Aclaris Therapeutics
ACRS
$209M
| $4.77M | 1.46% | 696,171 | – | – |
|
20
Immatics
IMTX
$619M
| $4.59M | 1.4% | 396,000 | – | – |
|
21
Prime Medicine
PRME
$578M
| $4.49M | 1.37% | 470,304 | – | – |
|
22
Immunocore
IMCR
$1.62B
| $4.2M | 1.29% | 80,963 | – | – |
|
23
Nkarta
NKTX
$151M
| $3.99M | 1.22% | 2,868,035 | – | – |
|
24
Janux Therapeutics
JANX
$1.37B
| $3.63M | 1.11% | 360,414 | – | – |
|
|
SYRS
25
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $3.48M | 1.07% | 881,450 | – | – |
|